In the claims:

1. (previously presented) A compound of the formula I



(I)

wherein

X is CH;

Y is NR_2CH_2, CH_2NR_2, NR_2CO, $CONR_2$ or NR_2SO_2

wherein R_2 is H or C_1-C_6 alkyl;

R_1 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl;

R_3 is C_1-C_6 alkyl, C_3-C_6 cycloalkyl or $(CH_2)_n$-aromatic ring,

wherein the aromatic ring is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S and wherein the aromatic ring may be mono- or di-substituted with R_4 and/or R_5;

wherein R_4 is H, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, halogen, CN, CF_3, OH, C_1-C_6 alkoxy, NR_6R_7, OCF_3, SO_3CH_3, SO_3CF_3, $SO_2NR_6R_7$, phenyl, phenyl-C_1-C_6 alkyl, phenoxy, C_1-C_6 alkylphenyl, an optionally substituted heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, O, S, SO and SO_2 wherein the substituent(s) is(are) selected from the group consisting of C_1-C_6 alkyl C_3-C_6 cycloalkyl and phenyl-C_1-C_6 alkyl, an optionally substituted heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S, wherein the substituent(s) is (are) selected from the group consisting of C_1-C_6 alkyl, C_3-C_6 cycloalkyl and phenyl-C_1-C_6 alkyl, or COR_8;

wherein R_6 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl;

R_7 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl; and

R_8 is C_1-C_6 alkyl, C_3-C_6 cycloalkyl, CF_3,NR_6R_7, phenyl, a heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S, or a heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, O, S, SO and SO_2;

wherein R_5 is H, OH, CF_3, OCF_3, halogen, C_1-C_6 alkyl or C_1-C_6 alkoxy;

n is 0-4;

R_9 is H, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, OCF_3, $OCHF_2$, OCH_2F, halogen, CN, CF_3, OH, C_1-C_6 alkoxy, C_1-C_6 alkoxy-C_1-C_6

alkyl, NR_6R_7, SO_3CH_3, SO_3CF_3, $SO_2NR_6R_7$, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S, wherein the substituent(s) is(are) C_1-C_6 alkyl; or COR_8; wherein R_6, R_7 and R_8 are as defined above,

wherein the compound is an *(R)*-enantiomer, an *(S)*-enantiomer, or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof.

2. (previously presented) The compound according to claim 1 wherein Y is NR_2CO or $CONR_2$.

3. (cancelled)

4. (previously presented) The compound according to claim 1 wherein R_1 is H or C_1-C_6 alkyl.

5. (previously presented) The compound according to claim 1 wherein R_3 is $(CH_2)_n$-aromatic ring.

6. (previously presented) The compound according to claim 5 wherein the aromatic ring of substituent R_3 is substituted with R_4, and R_4 is an optionally substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from the group consisting of N, O and S; or COR_8.

7. (previously presented) The compound according to claim 5 or 6 wherein n is 0.

8. (previously presented) The compound according to claim 6 wherein R_8 is NR_6R_7 or a heterocyclic ring containing two heteroatoms selected from N and O.

9. (previously presented) The compound according to claim 1 wherein R_9 is H, C_1-C_6 alkyl, $OCHF_2$, halogen or C_1-C_6 alkoxy.

10. (previously presented) The compound according to claim 1 wherein Y is NR_2CO and R_9 is C_1-C_6 alkoxy.

11. (previously presented) The compound according to claim 10 wherein R_4 is morpholino or COR_8.

12. (previously presented) The compound according to claim 1 wherein Y is NR_2CO and R_9 is C_1-C_6 alkyl.

13. (previously presented) The compound according to claim 12 wherein R_4 is morpholino or COR_8.

14. (previously presented) The compound according to claim 1 wherein Y is NR_2CO and R_9 is H.

15. (previously presented) The compound according to claim 14 wherein R_4 is morpholino or COR_8.

16. (cancelled)

17. (previously presented) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of claim 1, wherein the compound is an enantiomer or racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof optionally in association with diluents, excipients or inert carriers.

18. (previously presented) A method for the treatment of 5-hydroxytryptamine-mediated disorders, comprising administering to a patient in need of such treatment a

therapeutically effective amount of the pharmaceutical formulation of claim 17.

19. (previously presented) A method for the treatment of mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain, hypertension, urinary incontinence or vasospasm; or for inhibition of tumor growth, comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of claim 17.

20. (cancelled)

21. (previously presented) A method for the treatment of 5-hydroxytryptamine-mediated disorders in the central nervous system, comprising administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical formulation of claim 17.

22-29. (cancelled)

30. (previously presented) A method for the treatment of 5-hydroxytryptamine-mediated disorders in the central nervous system and/or urinary incontinence or vasospasm, or for inhibition of tumor growth, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound defined in claim 1.

31. (previously presented) The method according to claim 30 for the treatment of mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain or hypertension.

32. (cancelled)

33. (previously presented) A method for the treatment of 5-hydroxytryptamine-mediated disorders which require treatment with an h5-HT_{1B} antagonist, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound defined in claim 1.

34. (cancelled)

35. (cancelled)